0001487939-17-000002.txt : 20170815 0001487939-17-000002.hdr.sgml : 20170815 20170815142557 ACCESSION NUMBER: 0001487939-17-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170815 DATE AS OF CHANGE: 20170815 EFFECTIVENESS DATE: 20170815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synereca Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001487939 IRS NUMBER: 270530294 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-292834 FILM NUMBER: 171033516 BUSINESS ADDRESS: STREET 1: 865 RESEARCH PARKWAY STREET 2: SUITE 400 CITY: OKLAHOMA CITY STATE: OK ZIP: 73104 BUSINESS PHONE: 405-319-8165 MAIL ADDRESS: STREET 1: 865 RESEARCH PARKWAY STREET 2: SUITE 400 CITY: OKLAHOMA CITY STATE: OK ZIP: 73104 D 1 primary_doc.xml X0708 D LIVE 0001487939 Synereca Pharmaceuticals, Inc. 865 RESEARCH PARKWAY SUITE 400 OKLAHOMA CITY OK OKLAHOMA 73104 405-319-8165 DELAWARE None None Corporation true Richard E. Gammans 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Executive Officer Promoter Clayton I. Duncan 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Executive Officer Director Mark Corrigan 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Director Scott Meacham 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Director Bennett W. Love 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Director Scott F. Singleton 865 Research Parkway Suite 400 Oklahoma City OK OKLAHOMA 73104 Director Other Health Care Decline to Disclose 06b false 2017-08-02 false true false 0 1200000 600000 600000 false 10 0 0 0 Proceeds will be used for working capital, which may include normal compensation to executive officers. false Synereca Pharmaceuticals, Inc. Richard E. Gammans Richard E. Gammans President 2017-08-15